Advanced Biomed (ADVB) vs Insight Molecular Diagnostics (IMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Insight Molecular Diagnostics (IMDX) has outperformed Advanced Biomed (ADVB) over the past year, losing 10.9% versus a loss of 34.9%. Insight Molecular Diagnostics is the larger company by market cap ($107.7 million vs $9.8 million), about 10.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADVB | IMDX |
|---|---|---|
| Share price | $5.96 | $3.29 |
| Market cap | $9.85M | $107.66M |
| 1-day change | -5.40% | +0.30% |
| YTD return | +4.79% | -56.27% |
| 1-year return | -34.89% | -10.87% |
| 5-year return | — | -95.18% |
| P/E ratio (TTM) | 1.23 | — |
| EPS (TTM) | $4.85 | $-1.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.23 | $8.51 |
| 52-week low | $3.61 | $2.42 |
| Distance from 52-week high | -75.40% | -61.34% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +150.76% |
| Average volume | 1.75M | 232.87K |
| Shares outstanding | 1.65M | 32.72M |
| Employees | 31 | 55 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Insight Molecular Diagnostics is about 10.9 times larger than Advanced Biomed by market value ($107.66M vs $9.85M).
- IMDX has outperformed ADVB by 24.0 percentage points over the past year.
About Advanced Biomed
ADVB stock →Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product.
Health Care · Medical Specialities · 31 employees
About Insight Molecular Diagnostics
IMDX stock →Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 55 employees
ADVB vs IMDX FAQ
Which is bigger, Advanced Biomed or Insight Molecular Diagnostics?
Insight Molecular Diagnostics (IMDX) is larger, with a market capitalization of $107.66M compared with $9.85M for Advanced Biomed (ADVB).
Which stock has performed better over the past year, ADVB or IMDX?
IMDX returned -10.87% over the past 12 months, compared with -34.89% for ADVB (price return, excluding dividends). Past performance does not predict future results.
Are Advanced Biomed and Insight Molecular Diagnostics in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for Advanced Biomed and Biotechnology: In Vitro & In Vivo Diagnostic Substances for Insight Molecular Diagnostics.